Biotech Values

[akasidney86]

I find it interesting that the two companies estimates of the terms of the royalty agreement under multiple approval scenario are so different -- 12% and 20%. Yet they both come up with almost the same share valuation target... but curioser still, the 12% royalty gets a higher target ($17) than the 20% ($15).